Abstract
Osteoporosis is a multifactorial and debilitating disease resulting from decreased bone mineral density (BMD) and loss of tissue microarchitecture. Ineffective therapies may lead to bone fractures and subsequent death. Single nucleotide polymorphisms (SNPs) in key immune regulator genes have been associated with therapeutic response to bisphosphonates, which are the first therapeutic line of choice for osteoporosis. However, cytokine pathways and their relation with therapeutic adhesion remain to be fully elucidated. Aimed at better understanding these processes, we investigated the response to bisphosphonate therapy in postmenopausal women and four SNPs in key proinflammatory cytokines genes: IL23R +2284 (C>A) (rs10889677), IL17A +672 (G>A) (rs7747909), IL12B +1188 (T>G) (rs3212227) and INF-γ −1616 (G>A) (rs2069705). A total of 69 patients treated with bisphosphonate were followed for a period of 1 up to 4 years, genotyped and compared according to their changes in bone mineral density (BMD) and level of biochemical markers during their treatment. The INF-γ −1616 G/G associated with increased BMD values in femoral neck (GG/AA, p = 0.016) and decreased BMD values in total hip (GG/GA, p = 0.019; GG/AA, p = 0.011). In relation to biochemical markers, INF-γ −1616 SNP associated with increased alkaline phosphatase (GG/AA; p < 0.0001) and parathyroid hormone levels (AA/GA; p = 0.017). Vitamin D values changes were related to IL17A +672 (GG/GA, p = 0.034) and to IL12B +1188 (TT/TG, p = 0.046) SNPs. Besides, significant differences in changes of calcium levels correlated with IL23R +2284 (CC/CA, p = 0.016) genotypes. Altogether, we suggest that these polymorphisms may play an important role for therapeutic decisions in osteoporosis treatment.
Similar content being viewed by others
References
Abrahamsen B, Prieto-Alhambra D (2016) Patients with atypical femur fractures have the same mortality as the background population—drug-channelling bias, bisphosphonate effects and public health implications. J Bone Miner Res 31(3):488–490. doi:10.1002/jbmr.2801
Annunziato F, Romagnani C, Romagnani S (2015) The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immun 135(3):626–635. doi:10.1016/j.jaci.2014.11.001
Arron JR, Choi Y (2000) Bone versus immune system. Nature 408:535–536. doi:10.1038/35046196
Baccaro LF, Conde DM, Costa-Paiva L, Pinto-Neto AM (2015) The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging 10:583–591. doi:10.2147/CIA.S54614
Bignon JD, Viña MF (1995) 12th IHWC HLA Class II Reference Protocol. In: Fauchet R, Charron D (eds) Technical Handbook of the 12th International Histocompatibility Workshop. HLA et Médecine, Paris
Boroń D, Agnieszka SM, Daniel K, Anna B, Adam K (2014) Polymorphism of interleukin-17 and its relation to mineral density of bones in perimenopausal women. Eur J Med Res 16:19–69. doi:10.1186/s40001-014-0069-1
Carmeliet G, Dermauw V, Bouillon R (2015) Vitamin D signaling in calcium and bone homeostasis: a delicate balance. Best Pract Res Clin Endocrinol Metab 29(4):621–631. doi:10.1016/j.beem.2015.06.001
Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G (2016) Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 96(1):365–408. doi:10.1152/physrev.00014.2015
Cunha, EP, Steiner MI, Strufaldi R, Fernades C, Laurindo IMM, Pereira RMR, Simões R (2011) Osteoporose: Tratamento. Diretrizes Clínicas Na Saúde Suplementar. Associaçiação Médica Brasileira E Agência Nacional de Saúde Suplementar. http://diretrizes.amb.org.br/ans/osteoporose-tratamento.pdf. Accessed 01 August 2016
Czerny B, Kaminski A, Kurzawski M, Kotrych D, Safranow K, Dziedziejko V, Bohatyrewicz A, Pawlik A (2010) The Association of IL-1beta, IL-2, and IL-6 gene polymorphisms with bone mineral density and osteoporosis in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 149(1):82–85. doi:10.1016/j.ejogrb.2009.12.010
Damsker JM, Hansen AM, Caspi RR (2010) Th1 and Th17 Cells. Ann NY Acad Sci 1183:211–221. doi:10.1111/j.1749-6632.2009.05133.x.Th1
Drake MT, Clarke BL, Lewiecki EM (2015) The pathophysiology and treatment of osteoporosis. Clin Ther 37(8):1837–1850. doi:10.1016/j.clinthera.2015.06.006
Duque G, Huang DC, Dion N, Macoritto M, Rivas D, Li W, Yang XF, Li J, Lian J, Marino FT, Barralet J, Lascau V, Deschênes C, Ste-Marie LG, Kremer R (2011) Interferon-G plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Miner Res 26(7):1472–1483. doi:10.1002/jbmr.350
Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R (2007) IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 117(1):122–132. doi:10.1172/JCI30074
Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137–1148. doi:10.1002/jbmr.5650080915
Guerrini MM, Takayanagi H (2014) The immune system, bone and RANKL. Arch Biochem Biophys 561:118–123. doi:10.1016/j.abb.2014.06.003
Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O’Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S (2012) A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol 26(2):220–227. doi:10.1210/me.2011-1032
Haynes DR (2006) Emerging and future therapies for the treatment of bone loss associated with chronic inflammation. Inflammopharmacology 14(5–6):193–197. doi:10.1007/s10787-006-0006-1
Hiligsmann M, Bours SPG, Boonen A (2015) A review of patient preferences for osteoporosis drug treatment. Curr Rheumatol Rep 17(9):61. doi:10.1007/s11926-015-0533-0
Iolascon G, Napolano R, Gioia M, Moretti A, Riccio I, Gimigliano F (2013) The contribution of cortical and trabecular tissues to bone strength: insights from Denosumab studies. Clin Cases Miner Bone Metab 10(1):47–51. doi:10.11138/ccmbm/2013.10.1.047
Iwakura Y, Ishigame H (2006) The IL-23/IL-17 axis in inflammation. J Clin Invest 116(5):1218–1222. doi:10.1172/JCI25982.8
Jadon D, Tillett W, Wallis D, Cavill C, Bowes J, Waldron N, Dixon A, Sengupta R, Barton A, Korendowych E, McHugh NJ (2013) Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. Rheumatology (UK) 52(2):261–266. doi:10.1093/rheumatology/kes254
Kanis JA (2008) Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Brussels
Kerschan-Schindl K (2016) Prevention and rehabilitation of osteoporosis. Wien Med Wochenschr 166:22–27. doi:10.1007/s10354-015-0417-y
Khader SA, Gopal R (2010) IL-17 in protective immunity to intracellular pathogens. Virulence 1(5):423–427. doi:10.4161/viru.1.5.12862
Kruk M, Ralston SH, Albagha OM (2009) LRP5 polymorphisms and response to risedronate treatment in osteoporotic men. Calcif Tissue Int 84(3):171–179. doi:10.1007/s00223-008-9207-5
Lee HJ, Kim H, Ku SY, Choi YM, Kim JH, Kim JG (2014) Association between polymorphisms in leptin, leptin receptor, and beta-adrenergic receptor genes and bone mineral density in postmenopausal Korean women. Menopause 21(1):67–73. doi:10.1097/GME.0b013e31829366ed
Legiran S, Brandi ML (2012) Bone mass regulation of leptin and postmenopausal osteoporosis with obesity. Clin Cases Miner Bone Metab 9(3):145–149
Liu S, Zhou Z, Wang C, Guo M, Chu N, Li C (2015) Associations between interleukin and interleukin receptor gene polymorphisms and risk of Gout. Nature Publishing Group. Sci Reports 5:13887. doi:10.1038/srep13887
López-Delgado L, Riancho-Zarrabeitia L, Riancho JA (2016) Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis. Expert Opin Drug Metab Toxicol 12(4):389–398. doi:10.1517/17425255.2016.1154533
Louahchi S, Allam I, Berkani L, Boucharef A, Abdesemed A, Khaldoun N, Nebbab A, Ladjouze A, Djidjik R (2016) Association study of single nucleotide polymorphisms of IL23R and IL17 in rheumatoid arthritis in the Algerian population. Acta Reumatol Port 41(2):151–157
Makras P, Delaroudis S, Anastasilakis AD (2015) Novel Therapies for Osteoporosis. Metab, Clin Exp 64(10):1199–1214. doi:10.1016/j.metabol.2015.07.011
Marini F, Brandi ML (2014) Pharmacogenetics of osteoporosis. Best Pract Res Clin Endocrinol Metab 28(6):783–793. doi:10.1016/j.beem.2014.07.004
Miller PD (2016) Underdiagnoses and undertreatment of osteoporosis: the battle to be won. J Clin Endocrinol Metab 101(4):852–859. doi:10.1210/jc.2015-3156
Nasr A, Allam G, Hamid O, Al-Ghamdi A (2014) IFN-gamma and TNF associated with severe falciparum malaria infection in saudi pregnant women. Malar J 13:314. doi:10.1186/1475-2875-13-314
Pham TT, Angus SP, Johnson GL (2014) MAP3K1: genomic alterations in cancer and function in promoting cell survival or apoptosis. Genes Cancer 4(11–12):419–426. doi:10.1177/1947601913513950
Raisz Lawrence G (2005) Science in medicine pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115(12):3318–3325. doi:10.1172/JCI27071.3318
Ramana CV, Gil MP, Schreiber RD, Stark GR (2002) Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 23(2):96–101. doi:10.1016/S1471-4906(01)02118-4
Raphael I, Nalawade S, Eagar TN, Forsthuber TG (2014) T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74(1):5–17. doi:10.1016/j.cyto.2014.09.011
Riancho JA, Hernández JL (2012) Pharmacogenomics of osteoporosis: a pathway approach. Pharmacogenomics 13(7):815–829. doi:10.2217/pgs.12.50
Roush K (2011) Prevention and treatment of osteoporosis in postmenopausal women: a review. Am J Nurs 111(8):26–35. doi:10.1097/01.NAJ.0000403358.44058.f7
Roy SK, Hu J, Meng Q, Xia Y, Shapiro PS, Reddy SP, Platanias LC, Lindner DJ, Johnson PF, Pritchard C, Pagés G, Pouyssegur J, Kalvakolanu DV (2002) MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc Natl Acad Sci USA 99(12):7945–7950. doi:10.1073/pnas.122075799
Sharma U, Pal D, Prasad R (2014) Alkaline phosphatase: an overview. Indian J Clin Biochem 29(3):269–278. doi:10.1007/s12291-013-0408-y
Sun T, Chen M, Lin X, Yu R, Zhao Y, Wang J (2014) The influence of osteoprotegerin genetic polymorphisms on bone mineral density and osteoporosis in Chinese Postmenopausal Women. Int Immunopharmacol 22(1):200–203. doi:10.1016/j.intimp.2014.06.023
Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KHG (2009) Interleukin-1 and IL-23 induce innate IL-17 production from Γδ T Cells, amplifying Th17 responses and autoimmunity. Immunity 31(2):331–341. doi:10.1016/j.immuni.2009.08.001
Swanberg M, McGuigan FE, Ivaska KK, Gerdhem P, Åkesson K (2012) Polymorphisms in the inflammatory genes CIITA, CLEC16A and IFNG influence BMD, bone loss and fracture in elderly women. PLoS One 7(10):e47964. doi:10.1371/journal.pone.0047964
Takayanagi H, Sato K, Takaoka A, Taniguchi T (2005) Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 208(4):181–193. doi:10.1111/j.0105-2896.2005.00337.x
Talaat RM, Sidek A, Mosalem A, Kholief A (2015) Effect of bisphosphonates treatment on cytokine imbalance between TH17 and Treg in osteoporosis. Inflammopharmacology 23(2–3):119–125. doi:10.1007/s10787-015-0233-4
Tastan Y, Kann PH, Tinneberg HR, Hadji P, Müller-Ladner U, Lange U (2016) Low bone mineral density and vitamin D deficiency correlated with genetics and other bone markers in female Turkish immigrants in Germany. Clin Rheumatol 35(11):2789–2795. doi:10.1007/s10067-016-3237-6
Tella SH, Gallagher JC (2014) Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 142:155–170. doi:10.1016/j.jsbmb.2013.09.008
Tu B, Liu S, Liu G, Yan W, Wang Y, Li Z, Fan C (2015) Macrophages derived from THP-1 promote the osteogenic differentiation of mesenchymal stem cells through the IL-23/IL-23R/β-catenin pathway. Exp Cell Res 339(1):81–89. doi:10.1016/j.yexcr.2015.10.015
Wang C, Zheng H, He JW, Zhang H, Yue H, Hu WW, Gu JM, Shao C, Fu WZ, Hu YQ, Li M, Liu YJ, Zhang ZL (2015) Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese Women with low bone mineral density. Pharmacogenomics J 15(2):158–164. doi:10.1038/tpj.2014.52
Wong LH, Sim H, Chatterjee-Kishore M, Hatzinisiriou I, Devenish RJ, Stark G, Ralph SJ (2002) Isolation and characterization of a human STAT1 gene regulatory element. inducibility by interferon (IFN) types I and II and role of IFN regulatory Factor-1. J Biol Chem 277(22):19408–19417. doi:10.1074/jbc.M111302200
Ye XL, Lu CF (2013) Association of polymorphisms in the leptin and leptin receptor genes with inflammatory mediators in patients with osteoporosis. Endocrine 44(2):481–488. doi:10.1007/s12020-013-9899-9
Yuan FL, Li X, Lu WG, Zhao YQ, Li CW, Li JP, Sun JM, Xu RS (2012) Type 17 T-helper cells might be a promising therapeutic target for osteoporosis. Mol Biol Rep 39(1):771–774. doi:10.1007/s11033-011-0797-z
Zhang J, Fu Q, Ren Z, Wang Y, Wang C, Shen T, Wang G, Wu L (2015) Changes of serum cytokines-related Th1/Th2/Th17 concentration in patients with postmenopausal osteoporosis. Gynecol Endocrinol 31(3):183–190. doi:10.3109/09513590.2014.975683
Zheng H, Wang C, He JW, Fu WZ, Zhang ZL (2015) OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese Women with Osteoporosis or Osteopenia. Pharmacogenet Genomics 26(1):12–19. doi:10.1097/FPC.0000000000000181
Zhou PR, Liu HJ, Liao EY, Zhang ZL, Chen DC, Liu J, Wu W, Xing XP, Xia WB, Xu L, Li M (2014) LRP5 polymorphisms and response to Alendronate treatment in Chinese postmenopausal women with osteoporosis. Pharmacogenomics 15(6):821–831. doi:10.2217/pgs.14.12
Zhou PR, Xu XJ, Zhang ZL, Liao EY, Chen DC, Liu J, Wu W, Jiang Y, Wang O, Xia WB, Xing XP, Xu L, Li M (2015) SOST polymorphisms and response to Alendronate treatment in postmenopausal Chinese women with osteoporosis. Pharmacogenomics 16(10):1077–1088. doi:10.2217/pgs.15.76
Acknowledgements
We thank the following Brazilian funding agencies: CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico), and FACEPE (Fundação de Amparo à Ciência e Tecnologia de Pernambuco) for financial support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors declared any conflict of interest related to this manuscript.
Rights and permissions
About this article
Cite this article
Lima, C.A.D., Javorski, N.R., Souza, A.P.O. et al. Polymorphisms in key bone modulator cytokines genes influence bisphosphonates therapy in postmenopausal women. Inflammopharmacol 25, 191–201 (2017). https://doi.org/10.1007/s10787-017-0322-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-017-0322-7